Chairman–Dr Ron Weinberger BSc (Hons), PhD
Ron Weinberger joined 3DMorphic initially to provide strategic advice to an early stage company. After working in academia and then in the biomedical sector, Dr Weinberger joined Nanosonics Ltd (NAN) in August 2004. He was involved in the listing of NAN on the ASX in 2007. Ron was appointed as Executive Director and Board Member, in July 2008 and held that Board role for 8 years. He was appointed as CEO in May 2011 and then Managing Director which position he held for almost three years. As CEO, Ron grew Nanosonics from a market capitalisation of approximately $100M to approximately $240M within 2 years in a challenging economic environment. He grew annual revenue from $2.3M revenue to $14.9M over the same period and positioned NAN for near-term profitability. Today NAN has a market cap. of about $800M. Ron has held multiple roles at NAN from heading R&D/Regulatory, strategically building the IP portfolio and establishing USA operations. In commercialising the NAN product portfolio he developed distribution agreements with multinational companies such as Toshiba in the UK and Miele Professional in Germany and was a signatory on the USA GE Healthcare distribution agreement. Ron was primarily responsible for developingNAN’s lead product, trophon, which is now sold globally with regulatory approvals in major markets including the USA. Recently at NAN, Ron has led a team identifying unique opportunities for NAN’s new products portfolio, developing the fundamental technologies as well as the business cases supporting them. Dr Weinberger will continue to provide strategic leadership capabilities to the 3DMorphic team including regulatory, intellectual property, and sales. Dr Weinberger holds a PhD in medical biochemistry from the University of Newcastle.
Chief Executive Officer: Anthony Harrington GAICD, MBA, B.Sc
A professional executive and non-executive director with over 20 years’ experience in senior roles in the $12 billion Australian medical device sector. Anthony has a total of 8 years accumulated executive directorship expertise and over 3 years’ non-executive directorship experience whilst serving as Vice- Chair on the board of the Medical Technology Association of Australia (MTAA).
Over 20 years’ experience in business management/development with particular emphasis on the successful commercialisation (including D&D to realisation) of high tech medical devices, health tech platforms and multi-site technical services to major public and private hospitals; aged care facilities; pharmacies and primary care clinics in Australia, the UK, Europe and New Zealand. Anthony possesses high order marketing, analytical and investment skills developed via a range of line management roles in the medical device sector in Australia, New Zealand and the UK, coupled with the development and execution of innovative sales and marketing approaches to consistently over-deliver expected sales/ earnings targets. Anthony also possesses direct and extensive merger and acquisition experience and change management process transformation experience.
Technology: Dr William C.H. Parr, PhD
Dr Parr holds a PhD in Computational Morphology and Anatomy (University College London and the Natural History Museum, London), and is currently a Post-Doctoral Research Fellow at the Surgical and Orthopaedic Research Laboratory at the University of New South Wales having come to Australia on an Endeavour Postdoctoral Research Fellowship Award from the Australian Government in 2011. Dr Parr’s principal areas of expertise are in 3D modelling of anatomy, both with respect to statistical 3D shape analysis and biomechanical analyses (e.g. joint axis determination and bone kinematics, as well as Finite Element Analysis to predict stress and strain distributions), 3D reconstructions of anatomy (hard and soft tissue to create musculoskeletal models) from CT and MRI data, uses of additive manufacturing (3D printing) in medicine (3D printed anatomical models used during the planning of complex surgeries, replication of clinical anatomy to test biomedical devices, 3D printing of patient specific devices). Dr Parr has published peer reviewed scientific journal articles in top ranked journals, and has been an invited speaker at leading international research conferences. He has secured significant competitive government and private competitive merit based funding.
Clinical Advisor: Dr Ralph Mobbs, Neurosurgeon
Dr Ralph Mobbs is a Spinal Neurosurgeon at the Prince of Wales Private and Public Hospitals in Sydney, Australia. He is Director of the NeuroSpineClinic, Chair of the NSURG research group and Editor-in-Chief of the Journal of Spine Surgery, and is clinical Associate Professor in Neurosurgery at the University of New South Wales, Sydney. His clinical expertise is in the areas of spinal tumors, spinal trauma, and minimally invasive spine surgery for degenerative conditions. Over the last 15 years, he has developed new surgical fixation systems and implants, approaches and techniques in common use today. Research interests include: 3D Printing, Bio-materials, Disc Arthroplasty, Minimally Invasive surgical techniques, Wearable technologies, and Stem Cell regenerative therapies. Dr Mobbs is widely recognised as a global leader in the formulation and application of customised, 3d printed, spinal devices. Dr Mobbs is a Fellow of the Royal Australasian College of Surgeons.
Strategic Advisor: Andy Carter B.Sc, PhD
Dr Carter has worked with 3DMorphic since October 2017 and has more than 30 years leadership experience in the medical device industry and is an expert in orthobiologics, orthopaedics, and biomaterials with more than 30 US patents and patent applications.
Dr Carter is CTO at Theracell – a demineralised bone fiber technology business. His previous experience includes being the founder and President of Accent Biomedical, a provider of innovation services, and Chief Technology Officer at Anika Therapeutics, NASDAQ listed developer of hyaluronic acid based products for orthopedics, ophthalmics and aesthetic dermatology. Prior to this Dr Carter was Vice President R&D and General Manager at Spine Wave Inc. a Connecticut based start-up spine company. There he was responsible for development of injectable nucleus replacement and other motion preserving technologies. Dr Carter spent over twenty years at Smith & Nephew, both in the US and UK. As Group Director of R&D at Smith & Nephew Endoscopy in Boston, USA, Dr Carter led 80+ engineers developing implants and mechanical resection systems, fluid management systems for arthroscopy and endoscopy applications. Dr Carter also led Smith & Nephew’s successful efforts to improve the effectiveness of the product development process. As Program Manager for Orthopedics and Endoscopy and Head of Materials Research at Smith & Nephew’s Group Research Center in York, UK Dr Carter formulated and led long term research programs in orthopedics, spine and endoscopy, setting up joint ventures in tissue engineering and collaborative research programs with numerous universities.
co-founder: Andrew Jones MA (Hons), M.Sc
Andrew Jones has led several ventures over 15 years incorporating complex technical applications and multi-disciplinary engineering teams to commercialise technologies and value propositions in new markets. Andrew worked for six years for an London Stock Exchange-listed design engineering group leading initiatives on energy and process engineering technology. He has worked as a strategic advisor to the boards of both public and private companies, on aspects of business partnerships, and technology feasibility, adoption pathways, management and investment. He led a global metals technology proposition for process manufacturing with counterparts in China, North America and Europe, and a process engineering initiative with a US thermal oxidiser technology company with applicability in the semi-conductor manufacturing industry. Andrew was a Co-Founder and Director of renewable energy company Waratah Power Ltd, responsible for its applied Research & Development programmes and business development in Australia and Asia in which he led engineering and applied scientific teams from a variety of institutions to achieve commercial outcomes. Andrew has been working on the 3DMorphic proposition since August 2014 and is a co-founder and a major shareholder of the Company.